Craft

Hanmi Pharmaceutical

Stock Price

₩318.5 K

2024-04-29

Market Capitalization

₩4 T

2024-04-29

Revenue

₩1.3 T

FY, 2022

Hanmi Pharmaceutical Summary

Company Summary

Overview
Hanmi Pharmaceutical (한미약품(주)) is a company focused on the development and commercialization of pharmaceutical products. It develops treatments for diabetes, obesity, cancer, autoimmune, and other diseases. The company is also engages in cancer research, antibody platform technologies, etc.
Type
Public
Status
Active
Founded
2010
HQ
Seoul, KR | view all locations
Website
https://www.hanmipharm.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Jong-Soo Woo, President & CEO

    LocationsView all

    4 locations detected

    • Seoul, Seoul HQ

      Korea (Republic of)

      14 Wiryeseong-daero, Songpa-gu

    • Hwaseong, Gyeonggi-do

      Korea (Republic of)

      214 Muha-ro, Paltan-myeon

    • Hwaseong, Gyeonggi-do

      Korea (Republic of)

      550 Dongtangiheung-ro, Dongtan-myeon

    • Pyeongtaek, Gyeonggi-do

      Korea (Republic of)

      114 Chupalsandan-ro, Paengseong-eup

    Hanmi Pharmaceutical Financials

    Summary Financials

    Revenue (Q3, 2023)
    ₩364.6B
    Gross profit (Q3, 2023)
    ₩184.1B
    Net income (Q3, 2023)
    ₩60.5B
    Cash (Q3, 2023)
    ₩188.2B
    EBIT (Q3, 2023)
    ₩59.4B
    Enterprise value
    $4.4T

    Footer menu